Please login to your online account to display your discounted pricing

GE Healthcare Dharmacon ON-TARGETplus™ GAPD Control siRNA

Designed and modified to minimize off-target effects and improve silencing specificity

$181.47 - $181.47

Specifications

For Use With (Application) Validated positive controls siRNA for guaranteed silencing of GAPD, reduced off-targets due to the ON-TARGETplus™ dual-strand modifications, determination of optimal RNAi conditions
View More Specs
Products
Catalog Number Mfr. No. Species Quantity Price Quantity    

D0018300105

 
ge healthcare dharmacon
D-001830-01-05
Human 5nm Each for $181.47
Description & Specifications

Specifications

For Use With (Application) Validated positive controls siRNA for guaranteed silencing of GAPD, reduced off-targets due to the ON-TARGETplus™ dual-strand modifications, determination of optimal RNAi conditions

  • Validated positive controls siRNA for guaranteed silencing of GAPD (glyceraldehyde-3-phosphate dehydrogenase, also known as GAPDH) in human and mouse cells
  • Targets accession number NM_002046 (human) or NM_008084 (mouse) or XM_575242 (rat)

GAPD is an important enzyme in carbohydrate metabolism that is well conserved across the animal kingdom. This gene is abundantly expressed in most cells and because it is non-essential, knockdown of the corresponding mRNA does not affect cell viability.